has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The deal will include Aliada’s lead investigational product, ALIA-1758, which is in development for Alzheimer’s disease.
The gold standard of business intelligence. Aliada is at the forefront of advancing therapies with a blood-brain barrier (BBB)-crossing technology that targets transferrin and CD98 receptors, which are abundant in brain endothelial cells. This technology is integral to its Modular Delivery (MODEL) platform, engineered for precise central nervous system drug delivery.
ALIA-1758 employs the tech to transport an anti-pyroglutamate amyloid beta antibody across the BBB, aiming to degrade amyloid beta plaques associated with Alzheimer’s disease. The MODEL platform, originally developed by (J&J) scientists, is designed to deliver biological cargoes to the brain. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form These include therapeutic antibodies and genetic medicines such as small interfering RNA. The acquisition by AbbVie is expected to bolster the company’s research and development (R&D) capabilities, a.
